Florian Heil, Angelika Lahr, Norbert Wild, Oliver Krieter, Katharina Lechner, Mark M. Kockx, Simona Rossomanno, Suzana Vega Harring, Maria Martinez-Garcia, Christophe Massard, Manuel Hidalgo, Chia-Huey Ooi, Galina Babitzki, Peter Gerber, Christophe Le Tourneau, Alice Julien-Laferriere, Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Institut Gustave Roussy (IGR), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), MedImmune Chugai Pharmaceutical Berlin Mathematical School, BMS Ipsen Exelixis Eisai Gilead Sciences AstraZeneca Boehringer Ingelheim Agios Pharmaceuticals GlaxoSmithKline, GSK F. Hoffmann-La Roche Bristol-Myers Squibb Canada, BMS Celgene Astellas Pharma AbbVie Amgen Astex Pharmaceuticals Eli Lilly and Company Clovis Oncology Bayer Merck Sharp and Dohme, MSD Johnson and Johnson, J&J Janssen Biotech Daiichi Sankyo Company Genentech F. Hoffmann-La Roche, The following authors are employees and shareholders of Roche Diagnostics GmbH: FH, GB, OK, SVH, KL, AJL is an employee of Soladis GmbH, CHO is an employee and shareholder of F. Hoffmann-La Roche AG, PG was an employee of Roche Innovation Center at the time of manuscript preparation, now retired, SR is an employee of F. Hoffmann-La Roche, AL and NW are employees of Roche Diagnostics GmbH, MH has received honoraria for acting as a speaker, consultant or advisory board member (Celgene, Pfizer, Novartis, MSD, EMD, Ipsem, Shire, SOBI, Champions Oncology, Agenus, Erytech, Pharmacyte, Bioline, BioOncotech, Oncomatrix, VCN, Bayer, BMS, Nelum, Eng T Cells), holds stock (Champions Oncology, Pharmacyte, BioOncotech, Nelum, Eng T Cell), and has received royalties (Myriad) and financial support paid to his institution for clinical trials or research grants (Berg, Bioline, Pfizer, EMD, Celgene, ASANA, Bycicle, Oncomatrix, BioExcell, Erytech), CM has acted as principal/sub-investigator of clinical trials (AbbVie, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare AG, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech AG, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Exelixis, Forma, Gamamabs, Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, F. Hoffmann-La Roche AG, Incyte Corporation, Innate Pharma, Iris Servier, Janssen Cilag, Kura Oncology, Kyowa Kirin Pharm, Eli Lilly, Loxo Oncology, Lytix Biopharma AS, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Rigontec GmbH, F. Hoffmann-La Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc., Tioma Therapeutics, Inc., Xencor), received research grants (AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, F. Hoffmann-La Roche, Sanofi), received non-financial support (drug supplied) (AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Eli Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche) and received consultant/advisory fees (Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Eli Lilly, MedImmune, Novartis, Pfizer, F. Hoffmann-La Roche, Sanofi, Orion), MMG has acted as consultant/advisory board member (F. Hoffmann-La Roche) and received travel expenses (F. Hoffmann-La Roche, Pfizer), ClT has participated in advisory boards (AstraZeneca, F. Hoffmann-La Roche, MSD, BMS, Merck Serono, GSK, Nanobiotix, Amgen), M K is a co-founder and shareholder of HistoGeneX N.V., The clinical trial was sponsored by F. Hoffmann-La Roche. The sponsor was involved in all stages of the study, conduct and analysis. F. Hoffmann-La Roche also paid all costs associated with the development and the publication of the present manuscript., and Institut Curie [Paris]